$MNTA (Momenta Pharmaceuticals Inc.)

$MNTA {{ '2016-03-09T22:46:02+0000' | timeago}} • Announcement

$MNTA, a biotechnology company specializing in the characterization and engineering of complex drugs, said it elected Jose-Carlos (JC) Gutierrez-Ramos, Ph.D. to its Board of Directors effective March 9, 2016. Gutierrez-Ramos currently serves as CEO and President of Synlogic Inc.

$MNTA {{ '2017-07-21T18:24:56+0000' | timeago}} • Announcement

$MNTA announced that the jury in the District Court of Massachusetts in Boston issued its verdict finding that the company's U.S. patent covering methods for the manufacturing of generic Enoxaparin Sodium Injection was infringed, but invalid and unenforceable.

$MNTA {{ '2017-06-01T15:54:44+0000' | timeago}} • Announcement

$MNTA appointed Santiago Arroyo as Chief Medical Officer and SVP, Development. Arroyo joins Momenta from Boston Pharmaceuticals, where he was Chief Medical Officer.

$MNTA {{ '2017-02-21T13:42:48+0000' | timeago}} • Announcement

During 4Q16, $MNTA reported R&D expenses of $26.4MM, compared to $37.6MM during 4Q15. The 30% decrease was due to decreases of $6.8MM for Mylan's 50% share of biosimilar collaboration costs, and $3.3MM due to the discontinuation of the necuparanib development program.

$MNTA {{ '2017-02-21T13:35:57+0000' | timeago}} • Announcement

Biotechnology company $MNTA reported 4Q16 net income of $41.5MM, or $0.60 per share, compared to net loss of $29.2MM, or $0.43 per share in 4Q15. Total revenues rose to $34.2MM, up 52.6% YoY.

$MNTA {{ '2017-01-09T12:09:28+0000' | timeago}} • Announcement

$MNTA said it is currently assessing the U.S. GAAP accounting treatment for the Shire and CSL agreements and plans to discuss the accounting for these transactions, as well as provide 2017 financial guidance on its 4Q16 earnings call.

$MNTA {{ '2017-01-09T12:08:33+0000' | timeago}} • Announcement

$MNTA provided a corporate update and reviewed key anticipated highlights for 2017. $MNTA reiterated its 4Q16 non-GAAP operating expense forecast of about $40-45MM. $MNTA expects to report about $350MM of cash, cash equivalents and marketable securities at Dec. 31, 2016.

$MNTA {{ '2017-01-06T10:43:13+0000' | timeago}} • Announcement

$MNTA and CSL Limited expect to close the deal in 1Q17. Additionally, CSL and $MNTA intend to enter into a research collaboration to develop additional Fc multimer proteins that may originate from $MNTA's or CSL's research.

$MNTA {{ '2017-01-06T10:40:59+0000' | timeago}} • Announcement

$MNTA and CSL Limited announced entering into a research collaboration and worldwide license agreement to develop & commercialize Fc multimer proteins, including $MNTA's M230, a selective immunomodulator of Fc receptors. $MNTA will receive a $50MM upfront license fee from CSL and is eligible to receive future milestone & royalty payments for M230.

$MNTA {{ '2016-11-17T17:47:10+0000' | timeago}} • Announcement

$MNTA said data from preclinical studies on its M230, a novel autoimmune disease drug candidate, program were published in Science Translational Medicine. The data showed M230's ability to block immune complex-mediated damage and robust efficacy in preclinical.

$MNTA {{ '2016-09-23T12:21:23+0000' | timeago}} • Announcement

Biotech company $MNTA has named Corey Fishman to its Board of Directors, effective Sept. 22, 2016. At present, Mr. Fishman serves as CEO of Iterum Therapeutics Limited, a clinical-stage pharmaceutical company that specializes in creating marked anti-infectives for battling multi-drug resistant pathogens.

$MNTA {{ '2016-08-04T21:03:16+0000' | timeago}} • Announcement

In connection with the discontinuation of Necuparanib trial, $MNTA said that this decision was based on the recommendation from the independent Data Safety Monitoring Board (DSMB) following a planned interim futility analysis conducted once 57 deaths had occurred.

$MNTA {{ '2016-08-04T21:00:34+0000' | timeago}} • Announcement

Biotechnology company $MNTA said that the company has discontinued further accrual in its Phase 2 trial evaluating necuparanib drug in combination with Abraxane and gemcitabine drugs in patients with advanced metastatic pancreatic cancer.

$MNTA {{ '2016-06-23T16:34:40+0000' | timeago}} • Announcement

Biotechnology company $MNTA said that it appointed Steven Gilman to its Board of Directors effective June 22, 2016. The company also announced that Bennett Shapiro will no longer serve as a member of its Board of Directors following completion of his term ending on June 22, 2016.

$MNTA {{ '2016-03-09T22:46:02+0000' | timeago}} • Announcement

$MNTA, a biotechnology company specializing in the characterization and engineering of complex drugs, said it elected Jose-Carlos (JC) Gutierrez-Ramos, Ph.D. to its Board of Directors effective March 9, 2016. Gutierrez-Ramos currently serves as CEO and President of Synlogic Inc.

$MNTA {{ '2016-02-10T13:45:58+0000' | timeago}} • Announcement

Biotechnology company $MNTA said that the Federal Trade Commission (FTC) has granted early HSR Act clearance for the development and commercialization of six biosimilars with $MYL's subsidiary, Mylan Ireland Limited. The agreement is effective as of Feb. 9, 2016 and as per the deal, $MYL is obligated to pay $MNTA a $45MM upfront cash payment.

$MNTA {{ '2016-01-08T14:23:23+0000' | timeago}} • Announcement

Generic & specialty pharmaceuticals company $MYL said that it has agreed to join forces with $MNTA to develop, manufacture and commercialize six of $MNTA's biosimilar candidates, plus ORENCIA (abatacept). As per the agreement, $MYL will make an up-front cash payment of $45MM and up to $200MM in contingent milestone-related payments to $MNTA.

$BXLT {{ '2015-12-21T12:38:50+0000' | timeago}} • Announcement

$BXLT and $MNTA announced the initiation of a separate pivotal clinical trial of M923 in chronic plaque psoriasis in Oct.r 2015. $BXLT and $MNTA are targeting a first regulatory submission in 2017 and a first commercial launch as early as 2018.

$BXLT {{ '2015-12-21T12:37:46+0000' | timeago}} • Announcement

$BXLT and $MNTA say this study also evaluated safety, tolerability and immunogenicity following single doses of M923 given by injection. The safety profile and immunogenicity were also found to be comparable. A total of 324 healthy volunteers were enrolled in the study.

$BXLT {{ '2015-12-21T12:35:02+0000' | timeago}} • Announcement

$BXLT and $MNTA announced that M923, a proposed HUMIRA (adalimumab) biosimilar, met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. HUMIRA is a significant intervention for patients with autoimmune/inflammatory diseases.

$MNTA {{ '2015-12-07T16:17:55+0000' | timeago}} • Announcement

Biotechnology company $MNTA said it named Matt Ottmer as COO. He will report to CEO Craig Wheeler and will serve as a member of the executive committee. Ottmer will oversee the operational management of strategic product development, research, clinical development, and other commercial activities.

Recent Transcripts

NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 8:30pm
DEPO (DepoMed Inc.)
Tuesday, May 9 2017 - 8:30pm
AMRI (Albany Molecular Research Inc.)
Tuesday, May 9 2017 - 12:30pm
ACET (Aceto Corp.)
Friday, May 5 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, May 4 2017 - 12:30pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
MNTA (Momenta Pharmaceuticals Inc.)
Tuesday, May 2 2017 - 2:00pm
TECH (Bio-Techne Corp.)
Tuesday, May 2 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm
NVS (Novartis AG)
Tuesday, April 25 2017 - 12:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Monday, March 6 2017 - 1:30pm

AlphaGraphics you may like